The ReNew Hip implant developer won the inaugural OrthoPitch tech innovation competition at AAOS 2024, beating out more than 40 other nominees.
CytexOrtho co-founder and CEO Brad Estes said the startup has filed its FDA investigational device exemption (IDE) for a phase one clinical trial in the U.S., he told Medical Design & Outsourcing after his recent DeviceTalks Weekly interview. The company plans to seek FDA premarket approval (PMA) after a larger phase two pivotal trial.
DeviceTalks live and in person: Registration is now open for DeviceTalks Boston (May 1-2)
CytexOrtho (incorporated as…